Avid Bioservices Inc (CDMO)

[Protector]

swg_trd, the current CEO of THE GRAIL announced these 100-200 Bil$ numbers as being the cancer diagnostic market IF a complete test would be available (he said there wasn't and that without it the market was about 10-20 Bil$ for diagnostics). He said that in his previous CEO position.

It is the same guy that emphasised the problems with DNA based test and the mutation of DNA over time.

Furthermore you CANNOT compare Cancer Diagnostics with Cancer Treatment. PPHM Cheap, Fast and Simple Exosome based blood test with 100% accuracy ALSO has the properties that above mentioned CEO was referring to.

- binary cancer detection YES-NO
- Stage assessment
- benign or not
- cancer type detection
- treatment follow-up (progression-regression)

So we are NOT taking about ONLY initial detection, but we are looking at an alternative for the complete CANCER cycle from PRO-ACTIVE detection over qualification upto follow-up treatment.

Therefor your market value calculation doesn't hold because this PPHM test can accomplish things other then those that were traditionally included in what was called diagnostics. It will tap into the other related markets as listed above, follow-up possibly even being the biggest of all.

Last but not least such test will change the landscape of pro-active cancer testing, another reason why the number that you used will no longer be good measures.

If a Doctor can take a pro-active blood sample in stead of waiting till you have complaints and then find out what diagnostic technique would apply to see of you have a cancer that would match the complaints, then the threshold for patients will be MUCH LOWER.

Intestinal cancer requires anal-probe, and sometimes probe collected tissue for biopsy. Other cancers require biopsy, some others have a blood test, still others a pap smear and some radio (X-ray) to detect them. Many of them with lots of false positives/negatives. A simple, fast, cheap and reliable blood test as the one of PPHM will break that wall down.

This means that investing in the 100-200B Bil$ diagnostic market will cut down on the 100 Bil$ treatment market, a treatment market that with the new IO drugs and the new IP protection of the new pipelines will QUICKLY become a MUCH MORE expensive market as those treatment are about 3 to 4 times more expensive at least.

NO ONE could have written a paper on Global spending in cancer treatment and cancer diagnostics that would be correct ONES a NEW Exosome blood test as the one from PPHM came around. The report would have been written without taking into account the effect of such test.